Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Two decades and more than $200 billion later, AbbVie has finally lost its exclusive hold on the market for biologics based on Humira (adalimumab). 31 January 2023
Indian drugmaker Dr. Reddy’s Laboratories has completed the trial program for its proposed rituximab biosimilar candidate, and will move ahead with global regul 23 January 2023
Contract development and manufacturing organization (CDMO) Capstone Development has announced that its biosimilar version of insulin has received marketing auth 30 November 2022